Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
T Cells
100%
Phase I Trial
100%
Antibody Targeting
100%
Co-receptor
100%
Epithelial Cell Adhesion Molecule (EpCAM)
100%
Bispecific Monoclonal Antibody
100%
Catumaxomab
100%
Dose Effect
33%
Treatment-related Adverse Events
33%
Maximum Tolerated Dose
33%
Dose-limiting Toxicity
33%
Epithelial Cancer
16%
Liver Enzymes
16%
Bilirubin
16%
Intravenous Administration
16%
Dose Level
16%
Cytokine Release
16%
Liver Function Tests
16%
Prothrombin Time
16%
Supportive Care
16%
Dose-escalation Study
16%
Infusion Reaction
16%
Aspartate Aminotransferase
16%
Pyrexia
16%
Hematotoxicity
16%
Hepatotoxicity
16%
Hepatic Failure
16%
3 + 3 Design
16%
EpCAM Expression
16%
Bispecific Antibody
16%
Serum IL-6
16%
Tri-functional
16%
Epithelial Cancer Cells
16%
Pharmacology, Toxicology and Pharmaceutical Science
Monoclonal Antibody
100%
Phase I Trials
100%
Epithelial Cell Adhesion Molecule
100%
Catumaxomab
100%
Malignant Neoplasm
33%
Adverse Event
33%
Maximum Tolerated Dose
33%
Cytokine
16%
Symptom
16%
Hepatotoxicity
16%
Liver Enzyme
16%
Bilirubin
16%
Prothrombin
16%
Liver Failure
16%
Aspartate Aminotransferase
16%
Fever
16%
Chill
16%
Infusion Related Reaction
16%
Bispecific Antibody
16%